{"entity":{"id":"qin-shukui","kind":"person","name":"Shukui Qin","aka":["Qin Shu-Kui","秦叔逵"],"tldr":"Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use.","summary":"Principal investigator of CARES-310 (camrelizumab plus rivoceranib versus sorafenib, Lancet 2023), the donafenib versus sorafenib trial (Journal of Clinical Oncology 2021), apatinib in second-line HCC and many Chinese cohorts of global liver cancer trials; past president of the CSCO and author of its liver cancer guidelines. His trials reflect the hepatitis B-driven Chinese HCC population that differs from Western cohorts.","asOf":"2026-09-10","links":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qin%20S%5BAuthor%5D%20hepatocellular%20carcinoma%20Nanjing"}],"tags":["china"],"related":["csco"],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["camrelizumab-rivoceranib","donafenib","rivoceranib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cares-310","zgdh3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Nanjing Tianyinshan Hospital, China Pharmaceutical University (formerly Jinling Hospital, Nanjing)","specialisms":["Hepatocellular carcinoma","Gastrointestinal oncology","Clinical trials"],"profiles":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qin%20S%5BAuthor%5D%20hepatocellular%20carcinoma%20Nanjing"}],"papers":[{"title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00961-3"},{"title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma (ZGDH3)","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/JCO.20.02672"}]},"route":"/people/qin-shukui/","neighbours":{"institution":[{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"}],"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/"},{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/"},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/"}],"trial":[{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/"},{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/"}]}}